{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T22:28:01Z","timestamp":1789943281579,"version":"4.0.1"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2016,10,31]],"date-time":"2016-10-31T00:00:00Z","timestamp":1477872000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Allergy Asthma Rep"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1007\/s11882-016-0662-1","type":"journal-article","created":{"date-parts":[[2016,10,31]],"date-time":"2016-10-31T00:31:29Z","timestamp":1477873889000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Interleukin-5 Antagonists Usher in a New Generation of Asthma Therapy"],"prefix":"10.1007","volume":"16","author":[{"given":"Matthew P.","family":"Giannetti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan C.","family":"Cardet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,10,31]]},"reference":[{"key":"662_CR1","doi-asserted-by":"publisher","unstructured":"Centers for Disease Control and Prevention (CDC). Vital signs: asthma prevalence, disease characteristics, and self-management education: United States, 2001\u20142009. MMWR Morb Mortal Wkly Rep. 2011;60(17):547\u2013552. doi: 10.1109\/MMM.2008.930675 .","DOI":"10.1109\/MMM.2008.930675"},{"issue":"5","key":"662_CR2","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1111\/j.1398-9995.2004.00526.x","volume":"59","author":"M Masoli","year":"2004","unstructured":"Masoli M, Fabian D, Holt S, Beasley R. The global burden of asthma: executive summary of the GINA Dissemination Committee Report. Allergy Eur J Allergy Clin Immunol. 2004;59(5):469\u201378. doi: 10.1111\/j.1398-9995.2004.00526.x .","journal-title":"Allergy Eur J Allergy Clin Immunol"},{"issue":"6","key":"662_CR3","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1016\/j.jaci.2006.11.702","volume":"119","author":"P Chanez","year":"2007","unstructured":"Chanez P, Wenzel SE, Anderson GP, et al. Severe asthma in adults: what are the important questions? J Allergy Clin Immunol. 2007;119(6):1337\u201348. doi: 10.1016\/j.jaci.2006.11.702 .","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"662_CR4","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1183\/09031936.02.00232001","volume":"19","author":"P Godard","year":"2002","unstructured":"Godard P, Chanez P, Siraudin L, Nicoloyannis N, Duru G. Costs of asthma are correlated with severity: a 1-yr prospective study. Eur Respir J. 2002;19(1):61\u20137. doi: 10.1183\/09031936.02.00232001 .","journal-title":"Eur Respir J"},{"issue":"9643","key":"662_CR5","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1016\/S0140-6736(08)61452-X","volume":"372","author":"GP Anderson","year":"2008","unstructured":"Anderson GP. Endotyping asthma: new insights into key pathogenic mechanisms in a complex, heterogeneous disease. Lancet. 2008;372(9643):1107\u201319. doi: 10.1016\/S0140-6736(08)61452-X .","journal-title":"Lancet"},{"issue":"2","key":"662_CR6","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.jaci.2014.12.1871","volume":"135","author":"ML Fajt","year":"2015","unstructured":"Fajt ML, Wenzel SE. Asthma phenotypes and the use of biologic medications in asthma and allergic disease: the next steps toward personalized care. J Allergy Clin Immunol. 2015;135(2):299\u2013310. doi: 10.1016\/j.jaci.2014.12.1871 .","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"662_CR7","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.jaci.2010.11.037","volume":"127","author":"J Lotvall","year":"2011","unstructured":"Lotvall J, Akdis CA, Bacharier LB, et al. Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome. J Allergy Clin Immunol. 2011;127(2):355\u201360. doi: 10.1016\/j.jaci.2010.11.037 .","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"662_CR8","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.jaci.2013.05.007","volume":"132","author":"P Nair","year":"2013","unstructured":"Nair P. What is an \u201ceosinophilic phenotype\u201d of asthma? J Allergy Clin Immunol. 2013;132(1):81\u20133. doi: 10.1016\/j.jaci.2013.05.007 .","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"662_CR9","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1164\/rccm.200711-1754OC","volume":"178","author":"P Haldar","year":"2008","unstructured":"Haldar P, Pavord ID, Shaw DE, et al. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med. 2008;178(3):218\u201324. doi: 10.1164\/rccm.200711-1754OC .","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"662_CR10","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1164\/rccm.201109-1640OC","volume":"185","author":"KW McGrath","year":"2012","unstructured":"McGrath KW, Icitovic N, Boushey HA, et al. A large subgroup of mild-to-moderate asthma is persistently noneosinophilic. Am J Respir Crit Care Med. 2012;185(6):612\u20139. doi: 10.1164\/rccm.201109-1640OC .","journal-title":"Am J Respir Crit Care Med"},{"issue":"12","key":"662_CR11","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1093\/intimm\/dxp102","volume":"21","author":"T Kouro","year":"2009","unstructured":"Kouro T, Takatsu K. IL-5- and eosinophil-mediated inflammation: from discovery to therapy. Int Immunol. 2009;21(12):1303\u20139. doi: 10.1093\/intimm\/dxp102 .","journal-title":"Int Immunol"},{"issue":"3","key":"662_CR12","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1111\/cea.12480","volume":"45","author":"AB Kay","year":"2015","unstructured":"Kay AB. The early history of the eosinophil. Clin Exp Allergy. 2015;45(3):575\u201382. doi: 10.1111\/cea.12480 .","journal-title":"Clin Exp Allergy"},{"key":"662_CR13","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1055\/s-0029-1203812","volume":"17","author":"A Fraenkel","year":"1900","unstructured":"Fraenkel A. Zur Pathologie des Bronchialasthma. Deutsch Med Wchnschr. 1900;17:269.","journal-title":"Deutsch Med Wchnschr"},{"key":"662_CR14","doi-asserted-by":"crossref","unstructured":"Huber, H; Koessler K. The pathology of bronchial asthma. Arch Intern Med. 1922;30(6).","DOI":"10.1001\/archinte.1922.00110120002001"},{"issue":"1","key":"662_CR15","doi-asserted-by":"publisher","first-page":"10S","DOI":"10.1378\/chest.87.1.10S","volume":"87","author":"GJ Gleich","year":"1985","unstructured":"Gleich GJ, Loegering DA, Adolphson CR. Eosinophils and bronchial inflammation. Chest. 1985;87(1):10S\u20133S. doi: 10.1378\/chest.87.1.10S .","journal-title":"Chest"},{"issue":"5","key":"662_CR16","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1183\/09031936.00017707","volume":"29","author":"P Bradding","year":"2007","unstructured":"Bradding P. Mast cell regulation of airway smooth muscle function in asthma. Eur Respir J. 2007;29(5):827\u201330. doi: 10.1183\/09031936.00017707 .","journal-title":"Eur Respir J"},{"issue":"April","key":"662_CR17","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1172\/JCI115155","volume":"87","author":"RH Gundel","year":"1991","unstructured":"Gundel RH, Letts LG, Gleich GJ. Human eosinophil major basic protein induces airway constriction and airway hyperresponsiveness in primates. J Clin Invest. 1991;87(April):1470\u20133.","journal-title":"J Clin Invest"},{"issue":"3","key":"662_CR18","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1164\/ajrccm\/138.3.685","volume":"138","author":"NA Flavahan","year":"1988","unstructured":"Flavahan NA, Slifman NR, Gleich GJ, Vanhoutte PM. Human eosinophil major basic protein causes hyperreactivity of respiratory smooth muscle. Role of the epithelium. Am Rev Respir Dis. 1988;138(3):685\u20138. http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=3202421 .","journal-title":"Am Rev Respir Dis"},{"issue":"6","key":"662_CR19","first-page":"345","volume":"56","author":"E Frigas","year":"1981","unstructured":"Frigas E, Loegering D, Solley G, Farrow G, Gleich GJ. Elevated levels of the eosinophil granule major basic protein in the sputum of patients with bronchial asthma. Mayo Clin Proc. 1981;56(6):345\u201353.","journal-title":"Mayo Clin Proc"},{"issue":"12","key":"662_CR20","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1136\/thx.2006.073429","volume":"62","author":"M Berry","year":"2007","unstructured":"Berry M, Morgan A, Shaw DE, et al. Pathological features and inhaled corticosteroid response of eosinophilic and non-eosinophilic asthma. Thorax. 2007;62(12):1043\u20139. doi: 10.1136\/thx.2006.073429 .","journal-title":"Thorax"},{"issue":"5","key":"662_CR21","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1016\/j.jaci.2007.07.056","volume":"120","author":"SJ Arbes","year":"2007","unstructured":"Arbes SJ, Gergen PJ, Vaughn B, Zeldin DC. Asthma cases attributable to atopy: results from the Third National Health and Nutrition Examination Survey. J Allergy Clin Immunol. 2007;120(5):1139\u201345. doi: 10.1016\/j.jaci.2007.07.056 .","journal-title":"J Allergy Clin Immunol"},{"key":"662_CR22","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1164\/ajrccm.161.1.9802048","volume":"161","author":"R Louis","year":"2000","unstructured":"Louis R, Lau LCK, Bron AO, Roldaan AC. The relationship between airways inflammation and asthma severity. Am J Respir Crit Care Med. 2000;161:9\u201316.","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"662_CR23","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/S0091-6749(95)70265-2","volume":"96","author":"S Sur","year":"1995","unstructured":"Sur S, Gleich GJ, Swansonb MC, Bartemesb KR, Broide DH. Eosinophilic inflammation is associated with elevation of interleukin-5 in the airways of patients with spontaneous symptomatic asthma. J Allergy Clin Immunol. 1995;96(5):661\u20138. doi: 10.1016\/S0091-6749(95)70265-2 .","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"662_CR24","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1183\/09031936.00130008","volume":"35","author":"J Chakir","year":"2010","unstructured":"Chakir J, Loubaki L, Laviolette M, et al. Monitoring sputum eosinophils in mucosal inflammation and remodelling: a pilot study. Eur Respir J. 2010;35(1):48\u201353. doi: 10.1183\/09031936.00130008 .","journal-title":"Eur Respir J"},{"issue":"3","key":"662_CR25","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1183\/09031936.06.00137704","volume":"27","author":"L Jayaram","year":"2006","unstructured":"Jayaram L, Pizzichini MM, Cook RJ, et al. Determining asthma treatment by monitoring sputum cell counts: effect on exacerbations. Eur Respir J. 2006;27(3):483\u201394. doi: 10.1183\/09031936.06.00137704 .","journal-title":"Eur Respir J"},{"issue":"4","key":"662_CR26","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1164\/rccm.200906-0896OC","volume":"181","author":"WC Moore","year":"2010","unstructured":"Moore WC, Meyers DA, Wenzel SE, et al. Identification of asthma phenotypes using cluster analysis in the severe asthma research program. Am J Respir Crit Care Med. 2010;181(4):315\u201323. doi: 10.1164\/rccm.200906-0896OC .","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"662_CR27","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1183\/09031936.00120810","volume":"38","author":"V Siroux","year":"2011","unstructured":"Siroux V, Basagan X, Boudier A, et al. Identifying adult asthma phenotypes using a clustering approach. Eur Respir J. 2011;38(2):310\u20137. doi: 10.1183\/09031936.00120810 .","journal-title":"Eur Respir J"},{"issue":"5","key":"662_CR28","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1038\/nm.2678","volume":"18","author":"SE Wenzel","year":"2012","unstructured":"Wenzel SE. Asthma phenotypes: the evolution from clinical to molecular approaches. Nat Med. 2012;18(5):716\u201325. doi: 10.1038\/nm.2678 .","journal-title":"Nat Med"},{"issue":"6425","key":"662_CR29","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1038\/363172a0","volume":"363","author":"MV Milburn","year":"1993","unstructured":"Milburn MV, Hassell AM, Lambert MH, et al. A novel dimer configuration revealed by the crystal structure at 2.4 A resolution of human interleukin-5. Nature. 1993;363(6425):172\u20136. doi: 10.1038\/363172a0 .","journal-title":"Nature"},{"issue":"2","key":"662_CR30","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/nri3365","volume":"13","author":"H Spits","year":"2013","unstructured":"Spits H, Artis D, Colonna M, et al. Innate lymphoid cells\u2014a proposal for uniform nomenclature. Nat Rev Immunol. 2013;13(2):145\u20139. doi: 10.1038\/nri3365 .","journal-title":"Nat Rev Immunol"},{"issue":"6","key":"662_CR31","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.4049\/jimmunol.179.6.3452","volume":"179","author":"K Sakuishi","year":"2007","unstructured":"Sakuishi K, Oki S, Araki M, Porcelli SA, Miyake S, Yamamura T. Invariant NKT cells biased for IL-5 production act as crucial regulators of inflammation. J Immunol. 2007;179(6):3452\u201362.","journal-title":"J Immunol"},{"key":"662_CR32","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1084\/jem.175.1.293","volume":"175","author":"P Desreumaux","year":"1992","unstructured":"Desreumaux P, Janin A, Colombel JF, et al. Interleukin 5 messenger RNA expression by eosinophils in the intestinal mucosa of patients with coeliac disease. J Exp Med. 1992;175:293\u20136.","journal-title":"J Exp Med"},{"issue":"6","key":"662_CR33","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1182\/blood.V73.6.1504.1504","volume":"73","author":"E Clutterbuck","year":"1989","unstructured":"Clutterbuck E, Hirst E, Sanderson C. Human interleukin-5 (IL-5) regulates the production of eosinophils in human bone marrow cultures: comparison and interaction with IL-1, IL-3, IL-6, and GMCSF. Blood. 1989;73(6):1504\u201312.","journal-title":"Blood"},{"key":"662_CR34","doi-asserted-by":"crossref","unstructured":"Adachi T, Alam R. The mechanism of IL-5 signal transduction. Am J Physiol. 1998;275(3 Pt 1):C623-33. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/9730944\\nhttp:\/\/ajpcell.physiology.org\/content\/ajpcell\/275\/3\/C623.full.pdf .","DOI":"10.1152\/ajpcell.1998.275.3.C623"},{"key":"662_CR35","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1017\/CBO9781107415324.004","volume":"107","author":"R Alam","year":"1995","unstructured":"Alam R, Pazdrak K, Stafford S, Forsythe P. The interleukin-5\/receptor interaction activates Lyn and Jak2 tyrosine kinases and propagates signals via the Ras-Raf-1-MAP kinase and the Jak-STAT pathways in eosinophils. Int Arch Allergy Immunol. 1995;107:226\u20137. doi: 10.1017\/CBO9781107415324.004 .","journal-title":"Int Arch Allergy Immunol"},{"issue":"5","key":"662_CR36","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1084\/jem.172.5.1425","volume":"172","author":"LA Dent","year":"1990","unstructured":"Dent LA, Strath M, Mellor AL, Sanderson CJ. Eosinophilia in transgenic mice expressing interleukin 5. J Exp Med. 1990;172(5):1425\u201331. doi: 10.1084\/jem.172.5.1425 .","journal-title":"J Exp Med"},{"issue":"6 Pt 1","key":"662_CR37","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1164\/ajrccm\/142.6_Pt_1.1407","volume":"142","author":"M Azzawi","year":"1990","unstructured":"Azzawi M, Bradley B, Jeffery PK, et al. Identification of activated T lymphocytes and eosinophils in bronchial biopsies in stable atopic asthma. Am Rev Respir Dis. 1990;142(6 Pt 1):1407\u201313. doi: 10.1164\/ajrccm\/142.6_Pt_1.1407 .","journal-title":"Am Rev Respir Dis"},{"issue":"5","key":"662_CR38","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1056\/NEJM199201303260504","volume":"326","author":"D Robinson","year":"1992","unstructured":"Robinson D, Hamid Q, Ying S, et al. Predominant Th2-like bronchoalveolar T-lymphocyte population in atopic asthma. N Engl J Med. 1992;326(5):298\u2013304.","journal-title":"N Engl J Med"},{"issue":"5","key":"662_CR39","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1172\/JCI115166","volume":"87","author":"Q Hamid","year":"1991","unstructured":"Hamid Q, Azzawi M, Ying S, et al. Expression of mRNA for interleukin-5 in mucosal bronchial biopsies from asthma. J Clin Invest. 1991;87(5):1541\u20136. doi: 10.1172\/JCI115166 .","journal-title":"J Clin Invest"},{"issue":"1","key":"662_CR40","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1084\/jem.183.1.195","volume":"183","author":"PS Foster","year":"1996","unstructured":"Foster PS, Hogan SP, Ramsay AJ, Matthaei KI, Young IG. Interleukin 5 deficiency abolishes eosinophilia, airways hyperreactivity, and lung damage in a mouse asthma model. J Exp Med. 1996;183(1):195\u2013201. doi: 10.1084\/jem.183.1.195 .","journal-title":"J Exp Med"},{"issue":"3","key":"662_CR41","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1164\/ajrccm\/147.3.540","volume":"147","author":"CJ Corrigan","year":"1993","unstructured":"Corrigan CJ, Haczku A, Gemou-Engesaeth V, et al. CD4 T-lymphocyte activation in asthma is accompanied by increased serum concentrations of interleukin-5: effect of glucocorticoid therapy. Am Rev Respir Dis. 1993;147(3):540\u20137. doi: 10.1164\/ajrccm\/147.3.540 .","journal-title":"Am Rev Respir Dis"},{"issue":"2","key":"662_CR42","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1164\/ajrccm.152.2.7633694","volume":"152","author":"PJ Mauser","year":"1995","unstructured":"Mauser PJ, Pitman AM, Fernandez X, et al. Effects of an antibody to interleukin-5 in a monkey model of asthma. Am J Respir Crit Care Med. 1995;152(2):467\u201372. doi: 10.1164\/ajrccm.152.2.7633694 .","journal-title":"Am J Respir Crit Care Med"},{"key":"662_CR43","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1016\/S0140-6736(00)03496-6","volume":"356","author":"MJ Leckie","year":"2000","unstructured":"\u2022Leckie MJ, Ten Brinke A, Khan J, et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet. 2000;356:2144\u20138. doi: 10.1016\/S0140-6736(00)03496-6 . The first clinical trial to study anti-IL-5 medication. Did not improve airway hyper-responsiveness or the late asthmatic response.","journal-title":"Lancet"},{"issue":"13","key":"662_CR44","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1056\/NEJMoa1403291","volume":"371","author":"EH Bel","year":"2014","unstructured":"\u2022Bel EH, Wenzel SE, Thompson PJ, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med. 2014;371(13):1189\u201397. doi: 10.1056\/NEJMoa1403291 . Studied patients on maintenance with systemic corticosteroids. Mepolizumab reduced asthma exacerbations, daily dose of corticosteroids, and improved asthma symptom scores.","journal-title":"N Engl J Med"},{"key":"662_CR45","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","volume":"371","author":"HG Ortega","year":"2014","unstructured":"\u2022\u2022Ortega HG, Liu MC, Pavord ID, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371:1198\u2013207. doi: 10.1056\/NEJMoa1403290 . Large phase III study involving 573 patients with severe asthma. Mepolizumab reduced exacerbations and improved FEV1.","journal-title":"N Engl J Med"},{"issue":"5","key":"662_CR46","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/S2213-2600(15)00042-9","volume":"3","author":"M Castro","year":"2015","unstructured":"Castro M, Zangrilli J, Wechsler ME, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med. 2015;3(5):355\u201366. doi: 10.1016\/S2213-2600(15)00042-9 .","journal-title":"Lancet Respir Med"},{"key":"662_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2016.03.032","author":"L Bjermer","year":"2016","unstructured":"\u2022\u2022Bjermer L, Lemiere C, Maspero J, Weiss S, Zangrilli J, Germinaro M. Reslizumab for inadequately controlled asthma with elevated blood eosinophil levels: a randomized phase 3 study. Chest. 2016. doi: 10.1016\/j.chest.2016.03.032 . Reslizumab improves FEV1 and asthma symptom scores in patients with eosinophilic asthma.","journal-title":"Chest"},{"key":"662_CR48","doi-asserted-by":"publisher","unstructured":"\u2022Corren J, Weinstein S, Janka L, Zangrilli J, Garin M. Phase 3 study of reslizumab in patients with poorly controlled asthma: effects across a broad range of eosinophil counts. Chest. 2016. doi: 10.1016\/j.chest.2016.03.018 . Reslizumab does not improve FEV in an unselected group of patients with severe asthma. In a subset analysis of patients with peripheral eosinophilia >400\/\u03bcL, the FEV did improve. Emphasizes the importance of patient selection for reslizumab.","DOI":"10.1016\/j.chest.2016.03.018"},{"key":"662_CR49","doi-asserted-by":"publisher","unstructured":"\u2022\u2022Bleecker ER, Fitzgerald JM, Chanez P, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting \u03b2 2 -agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. 2016;6736(16):1\u201313. doi: 10.1016\/S0140-6736(16)31324-1 . First phase III study of benralizumab (sister trial published by Fitzgerald et al.) in severe asthmatics. Benralizumab reduces asthma exacerbations, and improves FEV 1 in patients with severe eosinophilic asthma, but may also be effective in those with non-eosinophilic asthma.","DOI":"10.1016\/S0140-6736(16)31324-1"},{"key":"662_CR50","doi-asserted-by":"publisher","unstructured":"\u2022\u2022Fitzgerald JM, Bleecker ER, Nair P, et al. Benralizumab, an anti-interleukin-5 receptor \u03b1 monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. 2016;6736(16):1\u201314. doi: 10.1016\/S0140-6736(16)31322-8 . Companion trial to Bleecker et al. Benralizumab reduces asthma exacerbations and improves FEV 1 in patients with severe eosinophilic asthma, but may also be effective in those with non-eosinophilic asthma.","DOI":"10.1016\/S0140-6736(16)31322-8"},{"issue":"2","key":"662_CR51","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1067\/mai.2001.116576","volume":"108","author":"TK Hart","year":"2001","unstructured":"Hart TK, Cook RM, Zia-Amirhosseini P, et al. Preclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeys. J Allergy Clin Immunol. 2001;108(2):250\u20137. doi: 10.1067\/mai.2001.116576 .","journal-title":"J Allergy Clin Immunol"},{"issue":"11","key":"662_CR52","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1164\/rccm.200701-085OC","volume":"176","author":"P Flood-Page","year":"2007","unstructured":"Flood-Page P, Swenson C, Faiferman I, et al. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am J Respir Crit Care Med. 2007;176(11):1062\u201371. doi: 10.1164\/rccm.200701-085OC .","journal-title":"Am J Respir Crit Care Med"},{"issue":"10","key":"662_CR53","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1056\/NEJMoa0805435","volume":"360","author":"P Nair","year":"2009","unstructured":"Nair P, Pizzichini MMM, Kjarsgaard M, et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med. 2009;360(10):985\u201393. doi: 10.1056\/NEJMoa0805435 .","journal-title":"N Engl J Med"},{"issue":"10","key":"662_CR54","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1056\/NEJMoa0808991","volume":"360","author":"P Haldar","year":"2009","unstructured":"Haldar P, Brightling CE, Hargadon B, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med. 2009;360(10):973\u201384. doi: 10.1056\/NEJMoa0808991 .","journal-title":"N Engl J Med"},{"issue":"9842","key":"662_CR55","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/S0140-6736(12)60988-X","volume":"380","author":"ID Pavord","year":"2012","unstructured":"\u2022Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012;380(9842):651\u20139. doi: 10.1016\/S0140-6736(12)60988-X . This was the largest study ever conducted in severe asthma when it was published. Showed a reduction in asthma exacerbations with mepolizumab.","journal-title":"Lancet"},{"issue":"12","key":"662_CR56","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1164\/rccm.200206-525OC","volume":"167","author":"JC Kips","year":"2003","unstructured":"Kips JC, O\u2019Connor BJ, Langley SJ, et al. Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study. Am J Respir Crit Care Med. 2003;167(12):1655\u20139. doi: 10.1164\/rccm.200206-525OC .","journal-title":"Am J Respir Crit Care Med"},{"issue":"10","key":"662_CR57","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1164\/rccm.201103-0396OC","volume":"184","author":"M Castro","year":"2011","unstructured":"Castro M, Mathur S, Hargreave F, et al. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am J Respir Crit Care Med. 2011;184(10):1125\u201332. doi: 10.1164\/rccm.201103-0396OC .","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"662_CR58","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1164\/rccm.200208-789OC","volume":"167","author":"PT Flood-Page","year":"2003","unstructured":"Flood-Page PT, Menzies-Gow AN, Kay AB, Robinson DS. Eosinophil\u2019s role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. Am J Respir Crit Care Med. 2003;167(2):199\u2013204. doi: 10.1164\/rccm.200208-789OC .","journal-title":"Am J Respir Crit Care Med"},{"key":"662_CR59","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1111\/cea.12695","volume":"46","author":"R Sehmi","year":"2015","unstructured":"Sehmi R, Smith SG, Kjarsgaard M, et al. Role of local eosinophilopoietic processes in the development of airway eosinophilia in prednisone-dependent severe asthma experimental allergy. Clin Exp Allergy. 2015;46:793\u2013802. doi: 10.1111\/cea.12695 .","journal-title":"Clin Exp Allergy"},{"issue":"1\u20132","key":"662_CR60","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3233\/HAB-2009-0198","volume":"18","author":"M Koike","year":"2009","unstructured":"Koike M, Nakamura K, Furuya A, et al. Establishment of humanized anti-interleukin-5 receptor alpha chain monoclonal antibodies having a potent neutralizing activity. Hum Antibodies. 2009;18(1\u20132):17\u201327. doi: 10.3233\/HAB-2009-0198 .","journal-title":"Hum Antibodies"},{"issue":"30","key":"662_CR61","doi-asserted-by":"publisher","first-page":"26733","DOI":"10.1074\/jbc.M202069200","volume":"277","author":"RL Shields","year":"2002","unstructured":"Shields RL, Lai J, Keck R, et al. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fc\u03b3RIII and antibody-dependent cellular toxicity. J Biol Chem. 2002;277(30):26733\u201340. doi: 10.1074\/jbc.M202069200 .","journal-title":"J Biol Chem"},{"issue":"6","key":"662_CR62","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1016\/j.jaci.2010.04.004","volume":"125","author":"R Kolbeck","year":"2010","unstructured":"Kolbeck R, Kozhich A, Koike M, et al. MEDI-563, a humanized anti-IL-5 receptor\u202falpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function. J Allergy Clin Immunol. 2010;125(6):1344\u20131353.e2. doi: 10.1016\/j.jaci.2010.04.004 .","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"662_CR63","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1016\/j.jaci.2013.05.020","volume":"132","author":"M Laviolette","year":"2013","unstructured":"Laviolette M, Gossage DL, Gauvreau G, et al. Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia. J Allergy Clin Immunol. 2013;132(5):1086\u20131096.e5. doi: 10.1016\/j.jaci.2013.05.020 .","journal-title":"J Allergy Clin Immunol"},{"issue":"11","key":"662_CR64","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/S2213-2600(14)70201-2","volume":"2","author":"M Castro","year":"2014","unstructured":"Castro M, Wenzel SE, Bleecker ER, et al. Benralizumab, an anti-interleukin 5 receptor \u03b1 monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. Lancet Respir Med. 2014;2(11):878\u201390. doi: 10.1016\/S2213-2600(14)70201-2 .","journal-title":"Lancet Respir Med"},{"key":"662_CR65","unstructured":"LLC GSK. Nucala (Mepolizumab) [package insert]. 2015;Philadelph."},{"key":"662_CR66","unstructured":"Cinqair (Reslizumab) [package insert]. 2015;Teva Respi(Frazer, PA)."},{"issue":"3","key":"662_CR67","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1016\/j.jaci.2013.11.026","volume":"133","author":"P Haldar","year":"2014","unstructured":"\u2022\u2022Haldar P, Brightling CE, Singapuri A, et al. Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: a 12-month follow-up analysis. J Allergy Clin Immunol. 2014;133(3):921\u20133. doi: 10.1016\/j.jaci.2013.11.026 . This study followed 56 patients after completion of a mepolizumab clinical trial. Suggests patients develop rebound eosionpihilia shortly after discontinuing mepolizumab and they return to baseline frequency of exacerbations 12 months after therapy.","journal-title":"J Allergy Clin Immunol"},{"key":"662_CR68","unstructured":"Tice JA, Ollendorf DA, Campbell JD, et al. Mepolizumab for the treatment of severe asthma with eosinophilia: effectiveness, value, and value-based price benchmarks. Inst Clin Econ Rev. 2016."}],"container-title":["Current Allergy and Asthma Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11882-016-0662-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11882-016-0662-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11882-016-0662-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,27]],"date-time":"2020-09-27T01:34:11Z","timestamp":1601170451000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11882-016-0662-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,31]]},"references-count":68,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["662"],"URL":"https:\/\/doi.org\/10.1007\/s11882-016-0662-1","relation":{},"ISSN":["1529-7322","1534-6315"],"issn-type":[{"value":"1529-7322","type":"print"},{"value":"1534-6315","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,31]]},"article-number":"80"}}